These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11444802)

  • 1. Alzheimer beta amyloid deposition enhanced by apoE epsilon4 gene precedes neurofibrillary pathology in the frontal association cortex of nondemented senior subjects.
    Yamaguchi H; Sugihara S; Ogawa A; Oshima N; Ihara Y
    J Neuropathol Exp Neurol; 2001 Jul; 60(7):731-9. PubMed ID: 11444802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype.
    Mann DM; McDonagh AM; Pickering-Brown SM; Kowa H; Iwatsubo T
    Neurosci Lett; 2001 May; 304(3):161-4. PubMed ID: 11343827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of apolipoprotein E in Alzheimer's disease and its significance].
    He SR; Liu DG; Wang S; Xia YJ
    Zhonghua Bing Li Xue Za Zhi; 2005 Sep; 34(9):556-60. PubMed ID: 16468304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E E4 allele.
    Mann DM; Iwatsubo T; Pickering-Brown SM; Owen F; Saido TC; Perry RH
    Neurosci Lett; 1997 Jan; 221(2-3):81-4. PubMed ID: 9121705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglial activation in Alzheimer disease: Association with APOE genotype.
    Egensperger R; Kösel S; von Eitzen U; Graeber MB
    Brain Pathol; 1998 Jul; 8(3):439-47. PubMed ID: 9669695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques.
    Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM
    JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype.
    Pletnikova O; Kageyama Y; Rudow G; LaClair KD; Albert M; Crain BJ; Tian J; Fowler D; Troncoso JC
    Neurobiol Aging; 2018 Nov; 71():72-80. PubMed ID: 30099348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.
    Vidal R; Calero M; Piccardo P; Farlow MR; Unverzagt FW; Méndez E; Jiménez-Huete A; Beavis R; Gallo G; Gomez-Tortosa E; Ghiso J; Hyman BT; Frangione B; Ghetti B
    Acta Neuropathol; 2000 Jul; 100(1):1-12. PubMed ID: 10912914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.
    Berg L; McKeel DW; Miller JP; Storandt M; Rubin EH; Morris JC; Baty J; Coats M; Norton J; Goate AM; Price JL; Gearing M; Mirra SS; Saunders AM
    Arch Neurol; 1998 Mar; 55(3):326-35. PubMed ID: 9520006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.
    Lue LF; Kuo YM; Roher AE; Brachova L; Shen Y; Sue L; Beach T; Kurth JH; Rydel RE; Rogers J
    Am J Pathol; 1999 Sep; 155(3):853-62. PubMed ID: 10487842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele.
    Pahnke J; Walker LC; Schroeder E; Vogelgesang S; Stausske D; Walther R; Warzok RW
    Acta Neuropathol; 2003 Jan; 105(1):25-9. PubMed ID: 12471457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E genotype and deposits of Abeta40 and Abeta42 in Alzheimer disease.
    McNamara MJ; Gomez-Isla T; Hyman BT
    Arch Neurol; 1998 Jul; 55(7):1001-4. PubMed ID: 9678319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebral β-amyloid deposition predicts HIV-associated neurocognitive disorders in APOE ε4 carriers.
    Soontornniyomkij V; Moore DJ; Gouaux B; Soontornniyomkij B; Tatro ET; Umlauf A; Masliah E; Levine AJ; Singer EJ; Vinters HV; Gelman BB; Morgello S; Cherner M; Grant I; Achim CL
    AIDS; 2012 Nov; 26(18):2327-35. PubMed ID: 23018443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner.
    Thal DR; Capetillo-Zarate E; Schultz C; Rüb U; Saido TC; Yamaguchi H; Haass C; Griffin WS; Del Tredici K; Braak H; Ghebremedhin E
    Acta Neuropathol; 2005 Nov; 110(5):459-71. PubMed ID: 16195918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.
    Drzezga A; Grimmer T; Henriksen G; Mühlau M; Perneczky R; Miederer I; Praus C; Sorg C; Wohlschläger A; Riemenschneider M; Wester HJ; Foerstl H; Schwaiger M; Kurz A
    Neurology; 2009 Apr; 72(17):1487-94. PubMed ID: 19339712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse Amyloid-β Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques.
    Abner EL; Neltner JH; Jicha GA; Patel E; Anderson SL; Wilcock DM; Van Eldik LJ; Nelson PT
    J Alzheimers Dis; 2018; 64(4):1307-1324. PubMed ID: 30040735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy.
    Tsuboi Y; Josephs KA; Cookson N; Dickson DW
    Neurology; 2003 Jan; 60(2):240-5. PubMed ID: 12552038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiles of β-Amyloid Peptides and Key Secretases in Brain Autopsy Samples Differ with Sex and APOE ε4 Status: Impact for Risk and Progression of Alzheimer Disease.
    Nyarko JNK; Quartey MO; Pennington PR; Heistad RM; Dea D; Poirier J; Baker GB; Mousseau DD
    Neuroscience; 2018 Mar; 373():20-36. PubMed ID: 29331531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain.
    Ingelsson M; Fukumoto H; Newell KL; Growdon JH; Hedley-Whyte ET; Frosch MP; Albert MS; Hyman BT; Irizarry MC
    Neurology; 2004 Mar; 62(6):925-31. PubMed ID: 15037694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.